Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-510- Thrombospondin-1 mimetic · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| ABT-510 - Thrombospondin-1 mimetic | DRUG | - |
Inclusion Criteria A subject will be eligible for study participation if all of the following criteria are met: * The subject is at least 18 years of age. * The subject has histologically confirmed high grade locally advanced or metastatic soft tissue sarcoma (excluding Ewings sarcoma and chondros...
ABT-510 was studied in oncology for the treatment of non-Hodgkin lymphoma and soft tissue sarcoma. It was evaluated in Phase 2 clinical trials in patients with refractory lymphoma and in patients with locally advanced or metastatic soft tissue sarcoma. It is an investigational agent and is not approved for commercial use.
ABT-510 was developed by Abbott Laboratories, which trades on the New York Stock Exchange under the ticker ABT. Abbott sponsored the Phase 2 clinical trials of ABT-510 in lymphoma and soft tissue sarcoma. The drug remains an investigational asset that has not received marketing approval.
ABT-510 reached Phase 2 clinical development. Two Phase 2 trials were conducted, one in refractory lymphoma and one in locally advanced or metastatic soft tissue sarcoma, and both are now completed. No later-stage trials have been initiated, and the drug is not approved for any indication.
ABT-510 was evaluated in two completed Phase 2 trials. NCT00061672 studied ABT-510 in subjects with refractory lymphoma and enrolled 67 patients. NCT00061659 studied ABT-510 in subjects with locally advanced or metastatic soft tissue sarcoma and enrolled 88 patients. Both trials were conducted in the United States.
Yes, ABT-510 and ABT-510 - Thrombospondin-1 mimetic refer to the same investigational compound. The longer name reflects the drug's classification as a thrombospondin-1 mimetic. Both names describe the same small molecule that Abbott Laboratories studied in Phase 2 oncology trials.
ABT-510 was studied in two cancer types: non-Hodgkin lymphoma, including Hodgkin's lymphoma, and soft tissue sarcoma. The lymphoma trial enrolled 67 patients with refractory disease, while the sarcoma trial enrolled 88 patients with locally advanced or metastatic disease. Both studies were Phase 2 and are completed.